Page 120 - 2019年10月第30卷第20期
P. 120

·药物与临床·


        灯盏生脉胶囊联合单硝酸异山梨酯对不稳定型心绞痛患者血清

        MMP-9、TIMP-1、血脂水平及心功能的影响                                          Δ


        唐 林 ,黎宗宝 ,白瑞娜(1.海南省人民医院中医科,海口 570311;2.海南省人民医院急救中心,海口
               1*
                         2
                                  3
        570311;3.中国中医科学院西苑医院心血管内科,北京 100091)
        中图分类号 R969          文献标志码 A          文章编号 1001-0408(2019)20-2851-04
        DOI  10.6039/j.issn.1001-0408.2019.20.22

        摘  要   目的:研究灯盏生脉胶囊联合单硝酸异山梨酯对不稳定型心绞痛(UAP)患者血清基质金属蛋白酶抑制因子1(TIMP-1)、
        基质金属蛋白酶9(MMP-9)、血脂水平及心功能的影响。方法:选择2016年4月-2019年4月在我院接受治疗的198例气虚血瘀
        型UAP患者为研究对象,根据治疗方案的不同将其分为观察组(n=102)和对照组(n=96)。对照组患者口服单硝酸异山梨酯片
        40 mg,qd;观察组患者在对照组基础上给予灯盏生脉胶囊口服,每次2粒,tid。两组均连续用药4周。比较两组患者的临床疗效、
        血清MMP-9和TIMP-1水平、血脂指标[低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、总胆固醇
       (TC)]和心功能指标[舒张末期容积(EDV)、左室射血分数(LVEF)、收缩末期容积(ESV)]。结果:观察组患者的总有效率明显高
        于对照组(91.18% vs. 70.83%,P<0.05)。治疗前,两组患者的MMP-9、TIMP-1、TC、LDL-C、TG、HDL-C、ESV、EDV、LVEF水平比
        较,差异均无统计学意义(P>0.05)。治疗后,两组患者的MMP-9、TC、LDL-C、TG、ESV、EDV水平较治疗前显著降低或减小,且
        观察组显著低于对照组;TIMP-1、HDL-C、LVEF水平均较治疗前显著升高或增加,且观察组显著高于对照组(P<0.05)。两组患
        者总不良反应发生率比较,差异无统计学意义(P>0.05)。结论:灯盏生脉胶囊联合单硝酸异山梨酯治疗UAP具有较好的临床疗
        效,能够有效降低患者血清MMP-9水平及提高血清TIMP-1水平,降低血脂水平,改善心功能,且安全性较好。
        关键词 灯盏生脉胶囊;单硝酸异山梨酯;不稳定型心绞痛;基质金属蛋白酶抑制因子-1;基质金属蛋白酶-9;血脂;心功能


        Effects of Dengzhan Shengmai Capsules Combined with Isosorbide Mononitrate on Serum MMP-9,
        TIMP-1,Blood Lipid Level and Cardiac Function in Patients with Unstable Angina Pectoris
        TANG Lin ,LI Zongbao ,BAI Ruina(1. Dept. of TCM,Hainan Provincial People’s Hospital,Haikou 570311,
                 1
                                        3
                             2
        China;2. Emergency Center,Hainan Provincial People’s Hospital,Haikou 570311,China;3. Dept. of
        Cardiovascular Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing
        100091,China)

        ABSTRACT   OBJECTIVE:To study the effects of Dengzhan shengmai capsules combined with isosorbide mononitrate on serum
        TIMP-1 and MMP-9 levels,blood lipid level and cardiac function in patients with unstable angina pectoris(UAP). METHODS:
        Totally 198 UAP patients admitted to our hospital from Apr. 2016 to Apr. 2019 were selected,and divided into observation group
       (n=102)and control group(n=96)according to therapy plan. Control group received Isosorbide mononitrate tablets 40 mg,qd,
        orally;observation group additionally received Dengzhan shengmai capsules,2 capsules per time,tid,orally,on the basis of
        control group. Both groups received treatment for consecutive 4 weeks. The clinical efficacy,serum levels of MMP-9 and TIMP-1,
        blood lipid indexes [low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C),triglyceride
       (TG),total cholesterol(TC)],cardiac function indexes [end-diastolic volume(EDV),left ventricular ejection fraction(LVEF),
        end-systolic volume(ESV)] and ADR were compared between 2 groups. RESULTS:The total response rate of observation group
        was significantly higher than control group(91.18% vs. 70.83%,P<0.05). Before treatment,there was no statistical significance
        in the levels of ESV,MMP-9,TIMP-1,TC,LDL-C,TG,HDL-C,EDV and LVEF between 2 groups (P>0.05). After
        treatment,the levels of MMP-9,TC,LDL-C,TG,ESV and EDV in 2 groups were decreased significantly in both groups,and
        the observation group was significantly lower than the control group(P<0.05);meanwhile,the levels of TIMP-1,HDL-C and
        LVEF in 2 groups were increased significantly,and the observation group was significantly higher than control group(P<0.05).
                                                           There was no statistical significance in the incidence of total
            Δ 基金项目:国家自然科学基金资助项目(No.81603489)
                                                           ADR in 2 groups (P>0.05). CONCLUSIONS: Dengzhan
           *主治医师,硕士。研究方向:中西医结合治疗心血管病。
        E-mail:irina919@163.com                            shengmai capsules combined with isosorbide mononitrate show


        中国药房    2019年第30卷第20期                                            China Pharmacy 2019 Vol. 30 No. 20  ·2851  ·
   115   116   117   118   119   120   121   122   123   124   125